| |
Financial Year 2008 - 2009
Quarter IV
(March 2009)
Quarter III
(December 2008)
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED
31ST DECEMBER 2006
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 31st December |
Nine months ended 31st december |
Year ended
31st March 2006
(Audited) |
| 2006 (Un Audited) |
2005 (Un Audited) |
2006 (Un Audited) |
2005 (Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
18. |
Sales (net)
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Materials Consumed
c) Staff Cost
d) Other Expenditure
Profit before R&D,Interest & Depreciation(1+2+3-4)
Research and Development Expenditure
Interest (net)
Depreciation
Profit before Tax(5-6-7-8)
Provision for Tax(Net)
Profit /(Loss) after Tax before Minority Interest and share in Associates (9-10)
Less : Minority Interest
Less : Share of loss in associate
Net Profit/ (Loss) (11-12-13)
Equity Capital
Reserves excluding revaluation reserves
E.P.S (Face value - Rs.2/-)
- Basic
- Diluted
Aggregate of Public Shareholding
-Number of shares - Face value of Rs.2 / - each
-Percentage of Shareholding
|
3,952.52
67.65
127.50
3468.42
100.24
2,099.52
447.77
820.89
679.25
262.86
203.97
148.24
64.18
67.37
(3.19)
(3.55)
(2.00)
(8.74)
307.96
-
(0.06)
(0.06)
(Not Annualised)
69,100,420
44.88%
|
3,338.01
67.65
1,091.03
2968.74
(81.24)
2,165.19
290.13
594.66
1527.95
104.54
99.98
94.26
1,229.17
221.06
1,008.11
(3.28)
1,004.83
306.47
-
6.71
6.53
(Not Annualised)
55,404,520
36.16%
|
12,105.90
202.22
261.09
10340.19
(162.63)
6,958.60
1,375.94
2,168.28
2229.02
666.14
555.42
413.84
593.62
86.37
507.25
(13.70)
(5.68)
487.87
307.96
-
3.17
3.10
(Not Annualised)
69,100,420
44.88%
|
7,797.23
202.22
1,309.78
6661.24
(281.98)
4,893.96
667.20
1,382.06
2647.99
246.26
138.47
232.62
2,030.64
325.75
1,704.89
(3.72)
1,701.17
306.47
-
11.36
11.09
(Not Annualised)
55,404,520
36.16%
|
11,586.15
268.39
1,400.81
9876.01
(293.27)
7,070.38
1,210.36
1,888.54
3379.34
393.73
268.84
335.05
2,381.72
376.09
2,005.63
(6.16)
(7.42)
1,992.05
307.26
9,420.63
13.23
12.99
68,750,750
44.75%
|
Segment Information
Segment Revenue:
-Pharmaceuticals
-Medical Supplies( Docpharma , Belgium )
Less: Inter segment Revenue
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
-Pharmaceuticals
-Medical Supplies( Docpharma , Belgium )
Total
Less: Interest
Other unallocable Income/(Expenditure)
Total Profit before tax
Capital Employed :
-Pharmaceuticals
-Medical Supplies( Docpharma , Belgium )
-Unallocable
Total Capital Employed :
|
3,369.16
583.36
-
3,952.52
188.12
80.03
268.15
(203.97)
64.18
13,162.22
299.24
12,011.86
25,473.33
|
2,736.73
601.28
-
3,338.01
1,320.13
9.02
1,329.15
(99.98)
1,229.17
7,106.80
218.39
8,212.91
15,538.10
|
10,381.86
1,724.04
-
12,105.90
1,028.80
120.24
1,149.09
(555.42)
593.62
13,162.22
299.24
12,011.86
25,473.33
|
6,712.93
1,084.30
-
7,797.23
2,099.48
69.63
2,169.11
(138.47)
2,030.64
7,106.80
218.39
8,212.91
15,538.10
|
9,974.62
1,611.53
-
11,586.15
2,572.64
77.92
2,650.56
(268.84)
2,381.72
7,840.72
178.68
14,614.55
22,633.95
|
|
| Notes : |
The above results were reviewed by the Audit Committee on 30th January 2007, considered and approved by the Board of Directors at their meeting held on 31st January 2007, and subject to limited review by Statutory Auditors.
The above results include the financials of Subsidiaries - Matrix Laboratories BV, Matrix Laboratories NV, Docpharma NV & its subsidiaries, Matrix Singapore Pte Ltd , Mchem Group, China , Matrix Inc , USA and Concord Biotech Limited, India and Joint Ventures Astrix Laboratories Limited and Fine Chemicals Limited.
The results for the quarter and nine month ended 31st December 2005 are not comparable with the current periods due to acquisitions at different points of time during the last year. Further the results of the previous quarter and nine months ended 31.12.05 had certain exceptional items which impacted the profit after tax favourably by Rs.685.90 millions.
MP Laboratories (Mauritius ) Ltd, a subsidiary of Mylan Laboratories Inc., (USA) vide agreement dated 28th August 2006 , acquired 51.5% of the outstanding shares of the Company at Rs. 306 per share , from certain shareholders on 8th January 2007. In terms of the SEBI takeover regulations they made an open offer and acquired further 20% from the remaining shareholders.
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 31st January 2007 |
Rajiv Malik
Chief Executive Officer
|
|
UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMBER,2006
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 31st December |
Nine months ended 31st december |
Year ended
31st March 2006
(Audited) |
| 2006 (Un Audited) |
2005 (Un Audited) |
2006 (Un Audited) |
2005 (Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15. |
Sales (net)
- Exports
- Domestic
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Materials Consumed
c) Staff Cost
d) Other Expenditure
Profit before R&D,Interest & Depreciation(1+2+3-4)
Research and Development Expenditure
Interest
Depreciation
Profit before Tax(5-6-7-8)
Provision for Tax(Net)
Profit after Tax (9-10)
Paid-up Equity Capital(Face value-Rs 2/-each)
Reserves excluding revaluation reserves
E.P.S (Face value - Rs.2/-)
- Basic
- Diluted
Aggregate of Public Shareholding
-Number of shares - Face value of Rs.2 / - each
-Percentage of Shareholding
|
1740.58
1196.92
543.66
67.65
54.25
1465.95
(304.37)
1252.50
151.68
366.14
396.53
214.09
42.80
64.31
75.33
8.78
66.55
307.96
-
0.43
0.42
(Not Annualised)
69,100,420
44.88%
|
1773.38
1122.12
651.26
67.65
1074.78
1570.84
(81.24)
1202.18
125.97
323.93
1344.97
71.26
25.87
59.02
1188.82
231.54
957.28
306.47
-
6.39
6.22
(Not Annualised)
55,404,520
36.16%
|
5107.13
3197.48
1909.65
202.22
203.96
4203.01
25.42
2823.00
438.53
916.09
1310.27
517.84
109.46
185.13
497.84
45.48
452.36
307.96
-
2.94
2.87
(Not Annualised)
69,100,420
44.88%
|
5060.46
2670.22
2390.24
202.22
1218.73
4242.24
(281.98)
3236.83
362.73
924.66
2234.17
190.42
53.92
168.27
1826.56
309.81
1516.75
306.47
-
10.13
9.89
(Not Annualised)
55,404,520
36.16%
|
6671.36
3959.88
2711.48
268.39
1317.26
5523.71
(167.83)
4029.84
480.00
1181.70
2733.30
311.19
81.50
223.42
2117.19
293.39
1823.80
307.26
8333.87
12.11
11.89
68,750,750
44.75%
|
|
| Notes : |
The above results were reviewed by the Audit Committee on 30th January 2007, considered and approved by the Board of Directors at their meeting held on 31st January 2007, and subject to limited review by Statutory Auditors.
The activities of the company relate to only one business segment i.e. Pharamaceuticals.
The results of the previous quarter and nine months ended 31.12.05 had certain exceptional items which impacted the profit after tax favourably by Rs.685.90 millions. The company also transferred a manufacturing unit to Astrix laboratories, its 50:50 joint venture with Aspen at the end of the previous third quarter. Hence the results of the current quarter and current nine months ended 31.12.06 are not comparable to the previous period results.
Provision for tax comprises Current Tax, Deferred tax and Fringe benefit tax.
MP Laboratories (Mauritius ) Ltd, a subsidiary of Mylan Laboratories Inc., (USA) vide agreement dated 28th August 2006 , acquired 51.5% of the outstanding shares of the Company at Rs. 306 per share , from certain shareholders on 8th January 2007. In terms of the SEBI takeover regulations they made an open offer and acquired further 20% from the remaining shareholders.
Summary of Investor Complaints
Opening : Nil , Received during the quarter : -- 3 , Resolved : -- 3 ,Closing : Nil
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 31st January 2007 |
Rajiv Malik
Chief Executive Officer
|
|
|
